Omeprazole does not change the oral bioavailability or pharmacokinetics of vinpocetine in rats

Pharmacological Reports

Volumn 63, Issue 5, 2011, Pages 1258-1263

  Sozański, Tomasz ^a   Magdalan, Jan ^a   Trocha, Małgorzata ^a   Szumny, Antoni ^b   Merwid La̧d, Anna ^a   Słupski, Wojciech ^a   Karaźniewicz Łada, Marta ^c   Kiełbowicz, Grzegorz ^b   Ksia̧dzyna, Dorota ^a   Szela̧g, Adam ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b WROC AW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Omeprazole; Oral bioavailability; Rats; Vinpocetine

Indexed keywords

OMEPRAZOLE; VINPOCETINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PH; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 83155181912     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70648-X     Document Type: Article

References (27)

1. Cui SX, Nie SF, Li L, Wang CG, Pan WS, Sun JP: Preparation and evaluation of self-microemulsifying drug delivery system containing vinpocetine. Drug Dev Ind Pharm, 2009, 35, 603-611.
2. Custodio JM, Wu CY, Benet LZ: Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev, 2008, 60, 717-733.
3. Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, Sjöstrand SE, Wallmark B: Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+, K+) ATPase. Nature, 1981, 290, 159-161. (Pubitemid 11149696)
4. Food and Drug Administration. Guidance for Industry (2002): Food-effect bioavailability and fed bioequivalence studies. Food and Drug Administration; Rockville, MD. Available at http://www.fda.gov/cder/guidance/index.htm.
5. Grandt R, Beitlinger H, Schaltenbrandt R, Braun W: Vinpocetine pharmacokinetics in erderly subjects. Arzneimittelforschung, 1989, 39, 1599-1602.
6. Harris RZ, Jang GR, Tsunoda S: Dietary effects on drug metabolism and transport. Clin Pharmacokinet, 2003, 42, 1071-1088. (Pubitemid 37357646)
7. Hurst S, Loi CM, Brodfuehrer J, El-Kattan A: Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin Drug Metab Toxicol, 2007, 3, 469-489. (Pubitemid 351324958)
8. Lohmann A, Dingler E, Sommer W, Schaffler K, Wober W, Schmidt W: Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung, 1992, 42, 914-917.
9. Lohmann A, Grobara P, Dingler E: Investigation of the possible influence of the absorption of vinpocetine with concomitant application of magnesium-aluminium - hydroxide gel. Arzneimittelforschung, 1991, 41, 1164-1167.
10. Manconi E, Binaghi F, Pitzus F: A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Curr Ther Res, 1986, 40, 702-709. (Pubitemid 16006119)
11. Miskolczi P, Kozma K, Polgar M, Vereczkey L: Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur J Drug Metab Pharmacokinet, 1990, 15, 1-5. (Pubitemid 20191269)
12. Nedelcheva V, Gut I: P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica, 1994, 24, 1151-1175.
13. Neuvonen PJ, Kivisto KT: Enhancement of drug absorption by antacids: an unrecognized drug interaction. Clin Pharmacokinet, 1994, 27, 120-128. (Pubitemid 24244852)
14. Nicholson CD: Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology, 1990, 101, 147-159.
15. Patyar S, Prakash A, Modi M, Medhi B: Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep, 2011, 63, 618-28.
16. Pudleiner P, Vereczkey L: Study on the absorption of vinpocetine and apovincaminic acid. Eur J Drug Metab Pharmacokinet, 1993, 18, 317-321. (Pubitemid 24099775)
17. Remon JP, Belpaire F, Van Severen R, Braeckman P: Interaction of antacids with antiarrhytmics. V. Effect of aluminium hydroxide and magnesium oxide on the bioavailability of quinidine, procainamide and propranolol in dogs. Arzneimittelforschung, 1983, 33, 117-120. (Pubitemid 13222120)
18. Richardson P, Hawkey CJ, Stack WA: Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs, 1998, 56, 307-335. (Pubitemid 28454260)
19. Singh BN: Effects of food on clinical pharmacokinetics. Clin Pharmacokinet, 1999, 37, 213-255.
20. Soons PA, van den Berg G, Danhof M, van Brummelen P, Jansen JB, Lamers CB, Breimer DD: Influence of single-and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol, 1992, 42, 319-324.
21. Szakács T, Veres Z, Vereczkey L: In vitro-in vivo correlation of the pharmacokinetics of vinpocetine. Pol J Pharmacol, 2001, 53, 623-628.
22. Vereczkey L, Czira G, Tamas J, Szentirmay Z, Botar Z, Szporny L: Pharmacokinetics of vinpocetine in humans. Arzneimittelforschung, 1979, 29, 957-960.
23. Vereczkey L, Szentirmai Z, Szporny L: Kinetic metabolism of vinpocetine in rat. Arzneimittelforschung, 1979, 29, 953-956.
24. Vereczkey L, Szporny L: Metabolism of ethyl apovincaminate in the rat. Arzneimittelforschung, 1976, 26, 1933-1938.
25. Washington C, Hou E, Hughes N, Berner B: Effect of omeprazole on bioavailability of an oral extendedrelease formulation of ciprofloxacin. Am J Health Syst Pharm, 2006, 63, 653-656.
26. Xu H, He L, Nie S, Guan J, Zhang X, Yang X, Pan W: Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. J Control Release, 2009, 140, 61-68.
27. Yao JH, Su CY, Chu XY: Pharmacokinetics and disposition of vinpocetine in rats. Acta Pharmacol Sin, 1994, 29, 81-85.